Statin induced myopathy epidemiology and demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby
Overview
The prevalence of statin induced myopathy is around 10 to 15%.[1]
Epidemiology and Demographics
The prevalence of statin induced myopathy, described as a spectrum of clinical conditions ranging from myalgia to myositis and rhabdomyolysis, is around 10 to 15%.[1]
References
- ↑ 1.0 1.1 Harper CR, Jacobson TA (2010). “Evidence-based management of statin myopathy”. Curr Atheroscler Rep. 12 (5): 322–30. doi:10.1007/s11883-010-0120-9. PMID 20628837.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH